A detailed history of Bank Of America Corp transactions in Profound Medical Corp. stock. As of the latest transaction made, Bank Of America Corp holds 203,090 shares of PROF stock, worth $1.42 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
203,090
Previous 203,290 0.1%
Holding current value
$1.42 Million
Previous $1.71 Million 5.22%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$7.47 - $11.18 $1,494 - $2,236
-200 Reduced 0.1%
203,090 $1.62 Million
Q2 2024

Aug 14, 2024

SELL
$7.25 - $9.07 $5,075 - $6,349
-700 Reduced 0.34%
203,290 $1.71 Million
Q1 2024

May 15, 2024

SELL
$7.3 - $9.46 $31,046 - $40,233
-4,253 Reduced 2.04%
203,990 $1.74 Million
Q4 2023

Feb 14, 2024

BUY
$7.85 - $11.18 $234,722 - $334,293
29,901 Added 16.77%
208,243 $1.77 Million
Q2 2023

Aug 14, 2023

BUY
$9.27 - $14.88 $7,434 - $11,933
802 Added 0.45%
178,342 $2.32 Million
Q1 2023

May 12, 2023

SELL
$8.85 - $13.27 $16,222 - $24,323
-1,833 Reduced 1.02%
177,540 $1.65 Million
Q4 2022

Feb 10, 2023

BUY
$3.18 - $10.91 $11,998 - $41,163
3,773 Added 2.15%
179,373 $1.95 Million
Q3 2022

Nov 14, 2022

BUY
$3.99 - $9.3 $391,419 - $912,330
98,100 Added 126.58%
175,600 $710,000
Q2 2022

Aug 12, 2022

SELL
$6.34 - $9.53 $5,566 - $8,367
-878 Reduced 1.12%
77,500 $564,000
Q1 2022

May 16, 2022

BUY
$8.16 - $11.33 $26,046 - $36,165
3,192 Added 4.25%
78,378 $706,000
Q4 2021

Feb 08, 2022

SELL
$10.38 - $15.2 $124,995 - $183,038
-12,042 Reduced 13.81%
75,186 $844,000
Q3 2021

Nov 15, 2021

BUY
$13.6 - $17.88 $503,771 - $662,310
37,042 Added 73.81%
87,228 $1.28 Million
Q2 2021

Sep 13, 2021

BUY
$16.0 - $20.59 $802,976 - $1.03 Million
50,186 New
50,186 $821,000

Others Institutions Holding PROF

About Profound Medical Corp.


  • Ticker PROF
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 20,851,300
  • Market Cap $146M
  • Description
  • Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops magnetic resonance guided ablation procedures for treatment of prostate disease, uterine fibroids, and palliative pain treatment in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system used for...
More about PROF
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.